(TB_PREV) Proportion of ART patients who completed a standard course of TB preventive therapy within the semiannual reporting period
This indicator measures the performance of HIV programs in scaling up TB preventive therapy, with the goal of preventing progression to active TB disease among PLHIV and decreasing ongoing TB transmission in this population. As part of a cascade from TX_CURR to TB screening (captured in TX_TB), this indicator will inform programs on the pace of scale-up, and the proportion will allow for monitoring of cohorts through completion of therapy. Disaggregates on type of therapy will inform programs on their relative use of different regimens, and the timing of ART will allow the clinical cascade to focus on those who are newly entering care, which will better demonstrate program performance, particularly in countries that have already provided TB preventive therapy for many of their PLHIV in care.
Number of ART patients who completed a course of TB preventive therapy during the reporting period (for continuous IPT programs, this includes the patients who have completed the first 6 months of isoniazid preventive therapy (IPT))
Number of ART patients who are expected to complete a course of TB preventive therapy during the reporting period (for programs using continuous IPT, this includes only the patients who are scheduled to complete the first 6 months of therapy)
How to calculate annual total:
When analyzing this data in conjunction with data on TB screening for ART patients (TX_TB), it is preferred to analyze it as a snapshot indicator and use the result reported at Q4. However, one could analyze the TB_PREV numerator independently of other data and sum the results across Q2 and Q4 to calculate the total number of ART patients who completed a course of TB preventive therapy during the fiscal year.
The numerator can be generated by counting the number of PLHIV on ART who are documented as having received at least six months of IPT or have completed another standard course of TB preventive therapy. This should include the patients who completed a shorter alternative course, such as 3 months of isoniazid and rifapentine (3HP), as well as those who are on prolonged or continuous IPT who have completed their first 6 months of therapy during the semiannual reporting period. Importantly, programs should ensure that patients on continuous therapy are counted only once, and not repeated in future calculations.
How to review for data quality:
1. Age/Sex by Type of TB Preventive Therapy (TPT) by ART Start: [Required]
The numerator can be generated by counting the number of PLHIV on ART who are documented as having received at least six months of IPT or have completed another standard course of TB preventive therapy.
The denominator can be generated by counting the total number of patients who are scheduled to complete a course of TB preventive therapy (or at least 6 months of IPT for those who are on a prolonged or continuous regimen) in the semiannual reporting period.
Indicator changes (MER 2.0 v2.2 to v2.3):
PEPFAR Support definition:
Data Visualization & Use Examples:
TB/HIV Prevention and Screening Cascade:
TB.2 TPT completion, 2020, WHO Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management (https://www.who.int/publications/i/item/consolidated-hiv-strategic-information-guidelines).